Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MingMed Approved to Start US Trial of Immunotherapy

publication date: Dec 2, 2021

MingMed, a Guangzhou biopharma, has been approved to start US clinical trials of its small-molecule HPK1 inhibitor for cancer immunotherapy. The company says HPK1 promotes exhaustion of tumor immunity. By targeting HPK1, PRJ1-3024 is designed to regulate several varieties of immune cells and activate their synergistic anti-tumor effects. MingMed has developed novel therapies in the fields of ophthalmology, medical aesthetics, immuno-oncology and gene editing-based immunotherapy. It has 10 products in its R&D pipeline, most of them first-in-class medications for unmet medical needs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital